Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. develops and commercializes medicines for genetic conditions through a decentralized biopharmaceutical model. News for BBIO centers on Attruby/acoramidis, its oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), including clinical data from ATTRibute-CM, commercial updates, Brazil marketing authorization under the BEYONTTRA name, and licensing or commercialization arrangements.
Company updates also cover late-stage genetic-disease programs such as encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and oral infigratinib for achondroplasia. Recurring financial and corporate items include quarterly results, product revenue trends, capital actions, employee equity inducement grants, investor conference participation, and pipeline regulatory disclosures.
BridgeBio Pharma and Maze Therapeutics have launched a joint venture, Contour Therapeutics, aimed at advancing precision medicine for genetically defined cardiovascular diseases. This partnership leverages Maze's genetic drug discovery and BridgeBio's expertise in cardiac drug development. Initially, they will develop treatments for a specific genetically defined heart failure type. The collaboration builds on significant progress in targeting genetic causes of cardiovascular disease, aiming to innovate treatment approaches for this leading global health issue.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced on December 1, 2020, the granting of stock options and restricted stock units to 15 new employees. A total of 15,351 stock options were granted at an exercise price of $51.13, along with 21,092 restricted stock units. This initiative was executed under the 2019 Inducement Equity Plan, aimed to incentivize new hires in compliance with Nasdaq Listing Rule 5635(c)(4). Founded in 2015, BridgeBio focuses on developing transformative medicines for genetic diseases and has over 20 development programs in its pipeline.
BridgeBio Pharma has announced the FDA's acceptance of their New Drug Application (NDA) for infigratinib, an oral FGFR1-3 selective inhibitor aimed at treating cholangiocarcinoma, a rare bile duct cancer. The NDA has been granted a Priority Review designation and is part of the Real-Time Oncology Review (RTOR) pilot program, expediting cancer treatments. This marks BridgeBio's second NDA acceptance, with plans for concurrent reviews in Australia and Canada through Project Orbis. Cholangiocarcinoma affects around 20,000 people annually in the U.S. and EU, with a low five-year survival rate of just 9%.
BridgeBio Pharma (Nasdaq: BBIO) and Navire Pharma have initiated a Phase 1 clinical trial for the SHP2 inhibitor BBP-398, targeting solid tumors with MAPK pathway mutations. The trial, led by MD Anderson’s David S. Hong, aims to evaluate safety and preliminary anti-tumor activity. The study consists of two parts, the first focusing on dose escalation to establish the recommended Phase 2 dose. BBP-398 emerged from collaborative research with MD Anderson, highlighting the potential of SHP2 inhibitors in treating hard-to-manage cancers.
BridgeBio Pharma (Nasdaq: BBIO) has executed a merger agreement with Eidos Therapeutics, aiming to enhance clinical and commercial capabilities for Eidos' acoramidis. The FDA accepted the New Drug Application for fosdenopterin for MoCD Type A under Priority Review. Financially, BridgeBio ended Q3 2020 with $710.7 million in cash and equivalents, a rise from $577.1 million at the end of 2019. However, operating expenses surged to $128.1 million for Q3 2020, up 58% from the previous year, resulting in a net loss of $130.2 million.
On November 1, 2020, BridgeBio Pharma (Nasdaq: BBIO) granted restricted stock units totaling 9,566 shares to three new employees. This initiative is intended to incentivize the employees as they join the company, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock awards are part of BridgeBio's 2019 Inducement Equity Plan, established to reward individuals who contribute to the company's goals. Founded in 2015, BridgeBio focuses on developing treatments for genetic diseases and has over 20 programs in its pipeline.
BridgeBio Pharma (Nasdaq: BBIO) announced the initiation of a Phase 2 study for BBP-589, an investigational recombinant collagen 7 (rC7) therapy, in patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic disorder. The trial is set to enroll six patients, assessing efficacy on wound healing and safety over 30 weeks. Previous Phase 1 results instill confidence in this potential therapy. BBP-589 has Orphan Drug Designation from the FDA and EMA, indicating promise for addressing unmet medical needs in rare diseases.
BridgeBio Pharma and the University of Colorado Anschutz Medical Campus announced a collaboration to advance research on genetically driven diseases into therapeutic applications. This expanded partnership follows an eight-month pilot collaboration, aiming to accelerate early-discovery research and commercialize promising therapies. The collaboration emphasizes a close partnership model between academia and the pharmaceutical industry, focusing on delivering breakthrough medicines for unmet patient needs. BridgeBio's pipeline includes over 20 development programs targeting Mendelian diseases and cancers with clear genetic drivers.
BridgeBio Pharma (Nasdaq: BBIO) has forged a three-year collaboration with the Salk Institute to advance research in genetically driven diseases, particularly in oncology. This partnership aims to translate innovative academic discoveries into therapeutic applications. Salk's cancer research will receive funding, facilitating the development of targeted therapies. Both organizations emphasize the importance of collaboration in accelerating scientific advancements and improving patient outcomes. This alliance marks a significant step in bridging academia and industry for impactful medical innovations.
BridgeBio Pharma (Nasdaq: BBIO) has announced plans to acquire all outstanding shares of Eidos Therapeutics (Nasdaq: EIDX) that it does not already own, equating to approximately 36.3% of Eidos’ shares. Eidos shareholders may choose either 1.85 shares of BridgeBio stock or $73.26 cash per share, with a cash limit of $175 million. This acquisition aims to streamline operations and utilize BridgeBio's development infrastructure to advance Eidos’ acoramidis, a treatment for ATTR, enhancing value for both patients and investors. The transaction is expected to close in Q1 2021, pending shareholder approval.